ANIP Q1 2024 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$137M+28.7% YoY

Gross Profit

$88M64.2% margin

Operating Income

$20M14.8% margin

Net Income

$18M13.2% margin

EPS (Diluted)

$0.83

QoQ Revenue Growth

+4.4%

Cash Flow

Operating Cash Flow

$18M

Free Cash Flow

$14M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$915M

Total Liabilities

$438M

Stockholders' Equity

$477M

Cash & Equivalents

$229M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$137M	$107M	+28.7%
Gross Profit	$88M	$69M	+27.8%
Operating Income	$20M	$10M	+105.3%
Net Income	$18M	$1M	+1165.3%

Revenue Segments

Generics, Established Brands, and Other

$100M73%

Rare Disease

$37M27%

Geographic Segments

UNITED STATES

$137M100%